FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

Warning Letters and Untitled Letters
to Pharmaceutical Companies
2006

These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office. This page only covers Division of Drug Marketing and Communications and Headquarters Warning Letters.  For District Office Warning Letters see the Main FDA FOI Warning Letters Page.    Some of the letters have been redacted or edited to remove confidential information. Click on the month to view the letters in Adobe Acrobat format.

Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter.  If you wish to obtain available additional information on the current status of an issue in a particular warning letter or notice of violation on this website, please contact the Agency or the recipient of the letter directly.  Inquiries to FDA should be sent to: Food and Drug Administration, Freedom of Information Staff (HFI-35), 5600 Fishers Lane, Rockville, MD 20857. Instructions for how to submit an FOI request can be found on the FDA FOI Page.

The letters are arranged in chronological order by month.  Click on the product name to view the letters in Adobe Acrobat (PDF) format. Go here for further information about Adobe Acrobat and download instructions.

Also see the "Cyber" Letters.

[2008] [2007] 2006 [2005] [2004] [2003] [2002] [2001] [2000] [1999] [1998] [1997]
December 2006
Product/Issue Company/Individual Division Released Posted

Dyrenium (triamterene) capsules

WellSpring DDMAC 12/19/2006 1/9/2007
November 2006
Product/Issue Company/Individual Division Released Posted

Seroquel

AstraZeneca DDMAC 11/16/2006 11/20/2006
October 2006
Product/Issue Company/Individual Division Released Posted
BMIS Inspection (Warning Letter) E. Clinton Lawrence, MD DSI 11/16/2006 4/15/2008

Maxair Autohaler (pirbuterol acetate inhalation aerosol) (Warning Letter)

3M Corporate Headquarters DDMAC 10/19/2006 10/20/2006

MD-GASTROVIEW (Warning Letter)

Mallinckrodt Inc. DDMAC 10/13/2006 10/18/2006

Nevanac (nepafenac ophthalmic suspension) (Warning Letter)

Alcon, Inc. DDMAC 10/20/2006 10/20/2006

ONTAK (denileukin diftitox) and Targretin (bexarotene) capsules (Warning Letter)

 

Ligand Pharmaceuticals, Inc. DDMAC 10/23/2006 10/25/2006

Orapred (prednisolone sodium phosphate oral solution) (Warning Letter)

 

BioMarin Pharmaceutical Inc. DDMAC 10/11/2006 10/11/2006
September 2006
Product/Issue Company/Individual Division Released Posted
Clinical Investigation (Warning Letter) Herman Zaharowitz, M.D. DSI 9/14/2006 9/26/2006
VoSpire ERQì (albuterol sulfate) Extended-Release Tablets (Warning Letter) DAVA Pharmaceuticals, Inc. DDMAC 9/21/2006 9/21/2006
Rythmol SR (propafenone HCl)extended release Capsules (Warning Letter) Reliant Pharmaceuticals, Inc. DDMAC 9/14/2006 9/15/2006
August 2006
Product/Issue Company/Individual Division Released Posted
BIMO inspection MDS Pharma Compliance 8/31/2006 9/11/2006
Clinical Investigation (Warning Letter) Professor Olga D. Ostroumova DSI 8/18/2006 10/5/2006
Prograf (tacrolimus capsules and injection) (Warning Letter) Astellas Pharma US, Inc. DDMAC 8/31/2006 9/5/2006
July 2006
Product/Issue Company/Individual Division Released Posted
Alimta (pemetrexed) for injection Eli Lilly and Company DDMAC 7/27/2006 7/31/2006
BMIS Inspection (Warning Letter) Evangeline G. Gonzalez, M.D. DSI 7/6/2006 8/10/2006
June 2006
Product/Issue Company/Individual Division Released Posted
Zovirax (acyclovir) Ointment (Warning Letter) GlaxoSmithKline DDMAC 6/30/2006 6/30/2006
Hydase (hyaluronidase Injection) (Warning Letter) PrimaPharm, Inc. DDMAC 6/29/2006 6/30/2006
Inspection (Warning Letter) Cell Point DSI 6/15/2006 7/21/2006
Inspection (Warning Letter) Massimo Cristofanilli, M.D. DSI 6/15/2006 7/21/2006
Inspection (Warning Letter) MD Anderson Cancer Center DSI 6/15/2006 7/21/2006
Site Inspection (Warning Letter) Ranbaxy DMPQ 6/15/2006 6/23/2006
May 2006
Product/Issue Company/Individual Division Released Posted
BMIS Inspection (Warning Letter) North American Science Associates, Inc. DSI 5/11/2006 5/22/2006
Bupropion hydrochloride extended-release tablets (SR) Sandoz DDMAC 5/26/2006 5/30/2006
Spiriva Handihaler Boehringer Ingelheim Pharmaceuticals DDMAC 5/25/2006 5/25/2006
April 2006
Product/Issue Company/Individual Division Released Posted
Site Inspection (Warning Letter) Pliva Croatia Ltd. Compliance 4/28/2006 5/5/2006
Sotradecol (sodium tetradecyl sulfate injection) (Warning Letter) Bioniche Pharma Group Limited DDMAC 4/4/2006 4/18/2006
March 2006
Product/Issue Company/Individual Division Released Posted
Site Inspection (Warning Letter) Wockhardh, Ltd. DMPQ 2/21/2006 4/10/2006
Infergen InterMune, Inc. DDMAC 3/28/2006 4/3/2006
February 2006
Product/Issue Company/Individual Division Released Posted
M.V.I.-12 (Multi-Vitamin Infusion without Vitamin K) (Warning Letter) Mayne Pharma (USA) DDMAC 2/12/2006 3/8/2006
(NeutroSpec Kit for the Preparation of Technetium (99m Tc fanolesomab) Palatin Technologies DDMAC 2/16/2006 3/3/2006
January 2006
Product/Issue Company/Individual Division Released Posted
Benicar (olmesartan) Warning Letter Sankyo Pharma, Inc. DDMAC 1/6/2006 1/11/2006
Cenestin (snythetic conjugated estrogens, A) (Warning Letter) Duramed DDMAC 1/4/2006 1/18/2006
IRB Inspection (Warning Letter) Human Investigation Committee of Houston, Texas DSI 1/23/2006 1/30/2006
Loprox Shampoo (ciclopirox) Medicis Pharmaceutical DDMAC 1/42006 1/11/2006

top arrow Back to Top     back arrow Index

Date created: January 11, 2006; updated April 15, 2008

horizonal rule